Tanaka Tomohito, Nishie Ruri, Ueda Shoko, Miyamoto Shunsuke, Hashida Sousuke, Konishi Hiromi, Terada Shinichi, Kogata Yuhei, Sasaki Hiroshi, Tsunetoh Satoshi, Taniguchi Kohei, Komura Kazumasa, Ohmichi Masahide
Department of Obstetrics and Gynecology, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
Translational Research Program, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan.
J Clin Med. 2022 May 6;11(9):2606. doi: 10.3390/jcm11092606.
Because patient-derived xenograft (PDX) models resemble the original tumors, they can be used as platforms to find target agents for precision medicine and to study characteristics of tumor biology such as clonal evolution and microenvironment interactions. The aim of this review was to identify articles on endometrial cancer PDXs (EC-PDXs) and verify the methodology and outcomes.
We used PubMed to research and identify articles on EC-PDX. The data were analyzed descriptively.
Post literature review, eight studies were selected for the systematic review. Eighty-five EC-PDXs were established from 173 patients with EC, with a total success rate of 49.1%. A 1-10 mm fragment was usually implanted. Fresh-fragment implantation had higher success rates than using overnight-stored or frozen fragments. Primary tumors were successfully established with subcutaneous implantation, but metastasis rarely occurred; orthotopic implantation via minced tumor cell injection was better for metastatic models. The success rate did not correspond to immunodeficiency grades, and PDXs using nude mice reduced costs. The tumor growth period ranged from 2 weeks to 13 months. Similar characteristics were observed between primary tumors and PDXs, including pathological findings, gene mutations, and gene expression.
EC-PDXs are promising tools for translational research because they closely resemble the features of tumors in patients and retain molecular and histological features of the disease.
由于患者来源的异种移植（PDX）模型类似于原始肿瘤，它们可作为寻找精准医学靶向药物以及研究肿瘤生物学特征（如克隆进化和微环境相互作用）的平台。本综述的目的是识别关于子宫内膜癌PDX（EC-PDX）的文章，并验证其方法和结果。
我们使用PubMed检索并识别关于EC-PDX的文章。对数据进行描述性分析。
文献综述后，选择了8项研究进行系统评价。从173例子宫内膜癌患者中建立了85个EC-PDX，总成功率为49.1%。通常植入1-10毫米的组织块。新鲜组织块植入的成功率高于使用过夜保存或冷冻组织块。原发性肿瘤通过皮下植入成功建立，但转移很少发生；通过注射切碎的肿瘤细胞进行原位植入对转移模型更好。成功率与免疫缺陷等级无关，使用裸鼠的PDX可降低成本。肿瘤生长周期为2周至13个月。原发性肿瘤和PDX之间观察到相似的特征，包括病理结果、基因突变和基因表达。
EC-PDX是转化研究中有前景的工具，因为它们与患者肿瘤的特征非常相似，并保留了疾病的分子和组织学特征。
